For the visual health of the next generation
Short-sightedness (myopia) is currently one of the fastest-growing vision problems worldwide – especially among children and adolescents. Studies show that both genetic factors and changing visual habits contribute to the progression of myopia.
The application of the myopic defocus concept is currently among the most effective solutions.
- Central monofocal zone, Ø 9–12 mm, with prescription value.
- Symmetrical defocus can be selected based on the wearer’s age for the defocus zone toward the edge of the lens.
Uncorrected
myopic eye
Corrected eye with
conventional lens
Corrected eye with
MyoSight lens
- 2.5 Dpt. Total defocus
- For children ages 5 to 8
- 25% thinner than a single-vision lens
- 1.6 Dpt. Total Defocus
- For children ages 9 to 12
- 18% thinner than a single-vision lens
- 1.0 Dpt. Total Defocus
- For teens ages 13 to 17
- 10% thinner than a single-vision lens
MyoSight was developed to provide young eyes with effective, practical support in the fight against the progression of myopia. Our white paper explains in detail how the innovative free-form design with circular defocus works and why it is one of the most effective noninvasive solutions for myopia management.
Particularly valuable:The white paper summarizes the results of a prospective, randomized, controlled, double-blind study that scientifically demonstrated the efficacy of MyoSight. After just 12 months, the 6- to 9-year-old age group showed a significant slowing of myopia progression and a 32% reduction in the increase in axial eye length compared to conventional single-vision lenses. As described in the white paper: “The data to date support the use of MyoSight lenses as an effective, noninvasive measure for controlling the progression of myopia.”
The white paper offers a compact, well-founded overview of design, technology, clinical data, and practical application – ideal for opticians who want to offer myopia management at the highest level.
MyoSight was developed to provide young eyes with effective, practical support in the fight against the progression of myopia. Our white paper explains in detail how the innovative free-form design with circular defocus works and why it is one of the most effective noninvasive solutions for myopia management.
Particularly valuable:The white paper summarizes the results of a prospective, randomized, controlled, double-blind study that scientifically demonstrated the efficacy of MyoSight. After just 12 months, the 6- to 9-year-old age group showed a significant slowing of myopia progression and a 32% reduction in the increase in axial eye length compared to conventional single-vision lenses. As described in the white paper: “The data to date support the use of MyoSight lenses as an effective, noninvasive measure for controlling the progression of myopia.”
The white paper offers a compact, well-founded overview of design, technology, clinical data, and practical application – ideal for opticians who want to offer myopia management at the highest level.
